MetaADEDB 2.0 @ LMMD
tofacitinib
(UJLAWZDWDVHWOW-YPMHNXCESA-N)
Structure
SMILES
N#CCC(=O)N1CC[C@H]([C@H](C1)N(c1ncnc2c1cc[nH]2)C)C
Type(s)
Approved; Investigational
ATC code(s)
L04AA29
Molecular Formula:
C16H20N6O
Molecular Weight:
312.370
Log P:
1.4827
Hydrogen Bond Acceptor:
6
Hydrogen Bond Donor:
1
TPSA:
88.91
CAS Number(s):
477600-75-2; 1259404-17-5
Synonym(s)
1.
tofacitinib
2.
CP 690,550
3.
CP 690550
4.
CP-690,550
5.
CP-690550
6.
CP690550
7.
Xeljanz
8.
tasocitinib
9.
tofacitinib citrate
External Link(s)
MeSHC479163
PubChem Compound9926791
BindingDB50193995
ChEBI71200
CHEMBLCHEMBL221959
DrugBankDB08895
DrugCentral4713
IUPHAR/BPS Guide to PHARMACOLOGY5677
KEGGdr:D09970
Therapeutic Target DatabaseD0EG1I
D0O2KL
ZINC3818808
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Product use in unapproved indicationFAERS: 9US FAERS
2Therapeutic response unexpectedFAERS: 9US FAERS
3Drug effective for unapproved indicationFAERS: 7US FAERS
4Pre-existing condition improvedFAERS: 5US FAERS
5Product use issueFAERS: 4US FAERS
6Drug ineffective for unapproved indicationFAERS: 3US FAERS
7Blood cholesterol increasedFAERS: 2US FAERS
8Drug administered to patient of inappropriate ageFAERS: 2US FAERS
9Drug ineffectiveFAERS: 2
Canada Vigilance: 1		Canada Vigilance
US FAERS
10HeadacheFAERS: 2SIDER
US FAERS
11InfectionFAERS: 2SIDER
US FAERS
12Abdominal discomfortFAERS: 1US FAERS
13Alopecia universalisFAERS: 124940651CTD
US FAERS
14ArthralgiaFAERS: 1SIDER
US FAERS
15Blood immunoglobulin G abnormalFAERS: 1US FAERS
16ClubbingFAERS: 1US FAERS
17DermatomyositisFAERS: 1US FAERS
18DizzinessFAERS: 1US FAERS
19EczemaFAERS: 1US FAERS
20EndocarditisFAERS: 1US FAERS
21Escherichia urinary tract infectionFAERS: 1US FAERS
22Gastric ulcerFAERS: 1US FAERS
23HypersensitivityFAERS: 1US FAERS
24Intestinal PerforationFAERS: 1US FAERS
25Joint swellingFAERS: 1SIDER
US FAERS
26Low density lipoprotein increasedFAERS: 1SIDER
US FAERS
27Micrococcus test positiveFAERS: 1US FAERS
28Musculoskeletal stiffnessFAERS: 1US FAERS
29NauseaFAERS: 1SIDER
US FAERS
30NeutropeniaFAERS: 1SIDER
US FAERS
31Omental infarctionFAERS: 1US FAERS
32PainFAERS: 1US FAERS
33Pancreatic carcinomaFAERS: 1US FAERS
34PneumoniaFAERS: 1SIDER
US FAERS
35Post procedural infectionFAERS: 1US FAERS
36PsoriasisFAERS: 1

View details

24883332
24940651
27059729
27267933
 		CTD
US FAERS
37Purpura FulminansFAERS: 1US FAERS
38Respiratory distressFAERS: 1US FAERS
39SepsisFAERS: 1US FAERS
40Septic ShockFAERS: 1US FAERS
41Skin UlcerFAERS: 1US FAERS
42SynovitisFAERS: 1US FAERS
43VasculitisFAERS: 1US FAERS
44Abdominal PainSIDER
45Adenoma27708194CTD
46Arthritis, Experimental

View details

21383241
21937456
22899318
22941906
 		CTD
47AstheniaSIDER
48Autoimmune Lymphoproliferative Syndrome26453583CTD
49Blood and lymphatic system disordersSIDER
50Blood creatinine increasedSIDER
51Bone Resorption22899318CTD
52Celiac Disease23269601CTD
53CellulitisSIDER
54CystSIDER
55DehydrationSIDER
56DermatitisSIDER
57Dry Eye Syndromes24342887CTD
58DyspepsiaSIDER
59Edema22899318CTD
60ErythemaSIDER
61FatigueSIDER
62GastritisSIDER
63Gastrointestinal PainSIDER
64HDL cholesterol increasedSIDER
65High density lipoprotein increasedSIDER
66Hyperplasia27708194CTD
67Inflammation21383241
22899318		CTD
68Leydig Cell Tumor27708194CTD
69Lipoma24141031CTD
70Lupus Erythematosus, Systemic27429362CTD
71LymphomaSIDER
72LymphopeniaSIDER
73MalnutritionSIDER
74Musculoskeletal PainSIDER
75Musculoskeletal discomfortSIDER
76NasopharyngitisSIDER
77PruritusSIDER
78TuberculosisSIDER
79Urinary tract infectionSIDER
80VomitingSIDER
81nervous system disorderSIDER
82treatment failureCanada Vigilance: 1Canada Vigilance
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.